FDA advisory committee votes against plan for broad use of prostate cancer drug
An FDA advisory committee on Friday voted against AstraZeneca and Merck’s bid to expand its Lynparza label to all adult patients with metastatic castration-resistant prostate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
